Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Xin Hui Chan

Xin Hui Chan

Social media

Xin Hui Chan

BMBCh MA MSc DPhil MRCP DTM&H DipRCPath


NIHR Academic Clinical Lecturer in Infectious Diseases

  • Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine

CLINICAL THERAPEUTICS FOR EMERGING INFECTIOUS DISEASES

Dr Xin Hui Chan is an NIHR Academic Clinical Lecturer in Infectious Diseases at the University of Oxford and an Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine at Oxford University Hospitals. Her current research focuses on accelerating the equitable development of clinical therapeutics for high-threat and emerging infectious diseases such as Nipah and dengue.

She leads a programme of work combining evidence synthesis, clinical trials, systems pharmacology, statistical modelling, and qualitative methods to optimise how we develop and deploy therapeutic interventions for the world's deadliest - and most neglected - infections.

She is a member of the UK Health Security Agency Malaria Expert Advisory Group and serves on the Editorial Boards of Travel Medicine and Infectious Disease and PLOS Global Public Health.

Xin Hui trained in medicine, infectious diseases, and tropical medicine in Oxford, London (LSHTM & University College London Hospitals), and Southeast Asia with further experience in North America (US National Institutes of Health), sub-Saharan Africa (MRC Unit The Gambia), and Southeastern Europe.

Her UK MRC-funded DPhil with Prof Sir Nick White at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) was a global evidence review of the cardiovascular safety of antimalarial medicines to optimise their development and deployment in collaboration with the WHO Global Malaria Programme. She was the WHO technical resource person and rapporteur of the WHO Evidence Review Group on the Cardiotoxicity of Antimalarial Medicines.